Clinical Trials Browser

Lymphoma, Non-Hodgkin × polatuzumab vedotin × 90 days × Clear all

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04739813 2026-06-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06040320 2026-05-27

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05171647 2026-05-07

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04844866 2026-04-29

DALY 2-EU

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin